At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 47 enrolled
Drug / intervention
CHF 4226 pMDI +3 moredrug
Likely dose
Moxifloxacin 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Single Dose, Positive and Placebo Controlled, Crossover Study of the Effects of Inhaled Carmoterol, at the Proposed Therapeutic and Supratherapeutic Doses, on the QTc Intervals in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating CHF 4226 pMDI, Placebo, and 1 other intervention for Chronic Obstructive Pulmonary Disease. Completed, enrolled 47 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effect of single doses of therapeutic and supratherapeutic doses of inhaled CHF 4226 pMDI on ventricular repolarization in healthy subjects compared with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedOct 2008
Primary CompletionDec 2008
TodayJul 2026
First PostedOct 22, 2008
Enrollment StartOct 1, 2008
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.7 years ago
Interventions
CHF 4226 pMDIdrug
Inhaled solution, single therapeutic dose
CHF 4226 pMDIdrug
Inhaled solution, single supratherapeutic dose
Placebodrug
Inhaled solution, single dose of placebo
Moxifloxacindrug
Tablet, oral, 400mg, single dose